Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership te
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early
01:34pm, Tuesday, 19'th May 2026
Corvus Pharmaceuticals, Inc. remains a Sell as its valuation has run ahead of fundamentals following encouraging but limited Phase 1 AD data. Soquelitinib shows activity in atopic dermatitis, but ques
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
04:26pm, Sunday, 17'th May 2026
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
06:50pm, Thursday, 14'th May 2026
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential fo
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 07'th May 2026
Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting t
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.
07:30am, Thursday, 23'rd Apr 2026
SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free r
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of “Moderate Buy” by Analysts
02:21am, Monday, 06'th Apr 2026
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the company, Mark
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% Following Weak Earnings
01:30am, Saturday, 14'th Mar 2026
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price fell 6.5% during trading on Friday following a dissappointing earnings announcement. The stock traded as low as $15.12 and l
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
09:32pm, Thursday, 12'th Mar 2026
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Thursday, 12'th Mar 2026
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
04:01pm, Thursday, 05'th Mar 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
04:01pm, Monday, 23'rd Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership t
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
10:39am, Monday, 02'nd Feb 2026
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obsc
